An upper limit of gonadotropin dose in patients undergoing ART should be advocated

References

• Ji J, Liu Y, Tong XH, et al. The optimum number of oocytes in IVF treatment: an analysis of 2455 cycles in China. Hum Reprod 2013;28:2728–34
   PubMed Web of Science ®Google Scholar
• Sterrenburg MD, Veltman-Verhulst SM, Eijkemans MJ, et al. Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis. Hum Reprod Update 2011;17:184–96
   PubMed Web of Science ®Google Scholar
• Out HJ, Braat DDM, Lintsen BME, et al. Increasing the daily dose of recombinant follicle stimulating hormone (Puregon1) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation. Hum Reprod 2000;15:29–35
   PubMed Web of Science ®Google Scholar
• Martin JR, Mahutte NG, Arici A, Sakkas D. Impact of duration and dose of gonadotrophins on IVF outcomes. Reprod Biomed Online 2006;13:645–50
   PubMed Web of Science ®Google Scholar
• Land JA, Yarmolinskaya MI, Dumoulin JC, Evers JL. High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome. Fertil Steril 1996;65:961–5
   PubMed Web of Science ®Google Scholar
• Haas J, Zilberberg E, Kedem A, et al. Do poor-responder patients benefit from increasing the daily gonadotropin dose from 300 to 450 IU during controlled ovarian hyperstimulation for IVF? Harefuah 2015;154:114–17
   PubMedGoogle Scholar
• Tarlatzis BC, Zepiridis L, Grimbizis G, Bontis J. Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum Reprod Update 2003;9:61–76
   PubMed Web of Science ®Google Scholar
• Siristatidis CS1, Hamilton MP. What should be the maximum FSH dose in IVF/ICSI in poor responders? J Obstet Gynaecol 2007;27:401–5
   PubMedGoogle Scholar
• Ferraretti AP1, La Marca A, ESHRE working group on Poor Ovarian Response Definition, et al. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011;26:1616–24
   PubMed Web of Science ®Google Scholar
• Ben Rafael Z, Benadiva C, Ausmanas M, et al. Dose of human menopausal gonadotropin influences the outcome of an in vitro fertilization program. Fertil Steril 1987;48:964–8
   PubMed Web of Science ®Google Scholar
• Hofmann G, Toner J, Muasher S, Jones G. High-dose follicle stimulating hormone (FSH) ovarian stimulation in low responder patients for in vitro fertilization. J In Vitro Fert Embryo Transf 1993;6:285–9
   Google Scholar
• Dorn C. FSH: what is the highest dose for ovarian stimulation that makes sense on an evidence-based level? Reprod Biomed Online 2005;11:555–61
   PubMed Web of Science ®Google Scholar
• Klinkert ER, Broekmans FJ, Looman CW, et al. Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Hum Reprod 2005;20:611–15
   PubMed Web of Science ®Google Scholar
• Lekamge DN, Lane M, Gilchrist RB, Tremellen KP. Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve. J Assist Reprod Genet 2008;25:515–21
   PubMed Web of Science ®Google Scholar
• Cedrin-Durnerin I, Bstandig B, Herve F, et al. A comparative study of high fixed-dose and decremental-dose regimens of gonadotropins in a minidose gonadotropin releasing hormone agonist flare protocol for poor responders. Fertil Steril 2000;73:1055–6
   PubMed Web of Science ®Google Scholar
• Berkkanoglu M, Ozgur K. What is the optimum maximal gonadotropin dosage used in microdose flare-up cycles in poor responders? Fertil Steril 2010;94:662–5
   PubMed Web of Science ®Google Scholar
• Lefebvre J, Antaki R, Kadoch IJ, et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertil Steril 2015;104:1419–25
   PubMed Web of Science ®Google Scholar
• Stadtmauer L, Ditkoff EC, Session D, Kelly A. High dosages of gonadotropins are associated with poor pregnancy outcomes after in vitro fertilization-embryo transfer. Fertil Steril 1994;61:1058–64
   PubMed Web of Science ®Google Scholar
• Pal l, Jindal S, Witt BR, Santoro N. Less is more: increased gonadotropin use for ovarian stimulation adversely influences clinical pregnancy and live birth after in vitro fertilization. Fertil Steril 2008;89:1694–701
   PubMed Web of Science ®Google Scholar
• Arce J-C, Andersen AN, Fernandez-Sanchez M, et al. Ovarian response to recombinant human folliclestimulating hormone: a randomized, antimullerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril 2014;102:1633–40
   PubMed Web of Science ®Google Scholar
• Xu YW, Peng YT, Wang B, et al. High follicle-stimulating hormone increases aneuploidy in human oocytes matured in vitro. Fertil Steril 2011;95:99–104
   PubMed Web of Science ®Google Scholar
• Baart EB, Martini E, Eijkemans JM, et al. Milder ovarian sitmulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Hum Reprod 2007;22:980–8
   PubMed Web of Science ®Google Scholar
• Verberg MF, Macklon NS, Nargund G, et al. Mild ovarian stimulation for IVF. Hum Reprod Update 2009;15:13–29
   PubMed Web of Science ®Google Scholar
• Kovacs P, Sajgo A, Kaali SG, Pal L. Detrimental effects of high-dose gonadotropin on outcome of IVF: making a case for gentle ovarian stimulation strategies. Reprod Sci 2012;19:718–24
   PubMed Web of Science ®Google Scholar
• Baker VL, Brown MB, Luke B, et al. Gonadotropin dose is negatively correlated with live birth rate: analysis of more than 650,000 assisted reproductive technology cycles. Fertil Steril 2015;104:1145–52
   PubMed Web of Science ®Google Scholar